SCHEMBL6511535

SCHEMBL6511535

Cc1cc(CC(=O)O)cc(C)c1Oc1ccc2[nH]cc(CC3CCCCC3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
THRB P10828 6/20 0.47
THRA P10827 5/20 0.47
HTR6 P50406 1/20 0.46
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
BCHE P06276 1/20 0.42
HTR1A P08908 3/20 0.41
HTR1B P28222 3/20 0.41
HTR1D P28221 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519373 0.99 KDM4E (0.50) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6516388 0.97 KDM4E (0.50) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6513989 0.95 KDM4E (0.52) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6512843 0.94 THRB (0.48) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6514396 0.94 THRB (0.49) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6518533 0.93 THRB (0.47) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6524625 0.93 THRB (0.48) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6515834 0.91 THRB (0.59) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6518611 0.91 KDM4E (0.46) KDM4ETHRBTHRAHTR6PPARG
SCHEMBL6519258 0.91 KDM4E (0.46) KDM4ETHRBTHRAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
EP-1347959-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed
WO-2002051805-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 KDM4E 1199/4885THRB 1772/4885THRA 2460/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP KDM4E 2994/4885THRB 1835/4885THRA 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.